The company said updated data from a Phase 2a clinical trial evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, will be presented at a symposium on Jan. 20-22.
New data demonstrate "compelling efficacy" from this combination regimen, driven by enhanced clinical responses and survival benefits.
Also to be presented are initial findings from the still-enrolling Part B of the trial, studying the same combination in second-line advanced gastric and gastroesophageal junction patients with high tumoral DKK1 expression, showing the treatment is "well tolerated with encouraging objective responses observed."
Shares of the company jumped 8.5% in the most recent pre-market activity on Wednesday.
Price: 2.96, Change: +0.24, Percent Change: +8.82